Navigation Links
GenVec to Present at the 2011 10th Annual BIO Investor Forum
Date:10/18/2011

GAITHERSBURG, Md., Oct. 18, 2011 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that Paul H. Fischer, Ph.D., GenVec's President and CEO, will present a Company overview highlighting recent developments at the 2011 10th Annual BIO Investor Forum on Tuesday, October 25, 2011 at 3:00 p.m. PDT at the Palace Hotel in San Francisco.

A webcast of Dr. Fischer's presentation will be available both live and on replay. The presentation will be available via webcast at http://www.veracast.com/webcasts/bio/investorforum2011/14112492.cfm. A replay will also be available for 90 days following the live presentation. The live webcast and subsequent archived replay of GenVec's presentation may also be accessed via the investors and media section of the Company's Web site at http://ir.genvec.com under "Events & Presentations."

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss, balance disorders, and cancer; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus type 2 (HSV-2), dengue fever, influenza, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional informat
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. GenVec Renews Stockholder Rights Plan
2. GenVec Reports First Quarter 2011 Financial Results
3. GenVec Regains Compliance with NASDAQ Listing Requirements
4. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
5. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
6. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
7. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
8. GenVec Reports Third Quarter 2009 Financial Results
9. GenVec Announces Third Quarter 2009 Results Conference Call
10. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
11. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... March 03, 2015 Experts and industry ... for one event: the Alltech REBELation exploring innovation, inspiration ... 17-20. Now in its 31st year, Alltech’s annual international ... countries, and the opportunity to join the REBELation at ... at 11:59 p.m. EST, at which point the standard ...
(Date:3/3/2015)... , March 3, 2015 /CNW/- SQI Diagnostics Inc. (TSX:V: ... proprietary technologies and products for advanced microarray diagnostics, ... CA, CFE  to its Management team. In his ... in its transition from a development stage to ... to advance the Company,s capital market strategy and ...
(Date:3/3/2015)... March 3, 2015  Regenicin, Inc. (OTC Bulletin Board: ... the development of and commercialization of regenerative cell therapies ... announced today that it has received the final payment ... Holdings, Inc. (OTC Bulletin Board: AMBS ). ... made the final payments due to Regenicin in the ...
(Date:3/3/2015)... Md. , March 3, 2015  RegeneRx Biopharmaceuticals, ... editorial in the scientific journal, Expert Opinion on ... his colleague, Dr. Zhenggang Zhang , at the ... reported that Thymosin beta 4 (TB4) has the ... remodeling 24 hours or more post-injury, leading to neurological ...
Breaking Biology Technology:World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4SQI Diagnostics Appoints Chief Financial Officer 2SQI Diagnostics Appoints Chief Financial Officer 3Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 2Regenicin (RGIN) Receives $2.3 Million in Final Payment from Amarantus 3Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 2Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases 3
... Allos,Therapeutics, Inc. (Nasdaq: ALTH ), a biopharmaceutical ... molecule therapeutics for,the treatment of cancer, today announced ... a corporate overview at the 2007 UBS Global ... presentation will take place at 3:30 p.m. (Eastern) ...
... Feature Public and Private Life Science Companies from ... ... for the,Southern California life science community, is proud to announce that ... Diego,Marriott Del Mar from Oct. 31-Nov. 2, 2007. Featuring almost ...
... Tissue Ligating ... ... surgical device company, has been named a 2007 Innovator of the,Year ... for its newest Tissue Ligating Shears, the TLS3,which uses the Company,s ...
Cached Biology Technology:Allos Therapeutics to Present at the 2007 UBS Global Life Sciences Conference 2BIOCOM Announces Second Annual Investor Conference 2Society of Laproendoscopic Surgeons Names Starion Instruments 2007 Innovator of the Year 2
(Date:3/3/2015)... FOREST, Calif. , March 3, 2015 ... the leading provider of advanced cryogenic logistics ... markets including immunotherapies, stem cells, cell lines, ... and reproductive medicine, today announced the expansion ... Cancer Research Centers, ("Fred Hutch") Clinical ...
(Date:3/2/2015)... , March 2, 2015  Businesses have ... Data protection company Tharon Rankins Enterprises has announced ... provides an ultra-safe way for businesses to protect ... financial transactions. Beconux is a ... Rankins Enterprises. Functioning similarly to an ATM machine, ...
(Date:2/25/2015)... LITTLE ROCK, Ark. , Feb. 25, 2015 ... of software and billing in the Health and ... software as well as to MYiCLUBonline.  The latest ... MYiCLUBonline and the inclusion of cardless check-in via ... demonstrated for the first time through interactive displays ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... PASADENA, Calif.A California Institute of Technology (Caltech)-led ... first proof that a targeted nanoparticleused as an ... bloodstreamcan traffic into tumors, deliver double-stranded small interfering ... gene using a mechanism known as RNA interference ...
... A potential new energy source so controversial that people once ... by the mainstream scientific community. That,s the conclusion of the ... topic "cold fusion" being held here for the ... National Meeting of the American Chemical Society (ACS). "Years ...
... , , Michael M. Graham, Ph.D., M.D., president, ... chair, SNM Medical Isotope Task Force, Jeffrey P. Norenberg, ... member, SNM Medical Isotope Task Force, WHEN:,Immediately ... over a two-week period when cancer, heart and brain ...
Cached Biology News:Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 2Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 3Caltech-led team provides proof in humans of RNA interference using targeted nanoparticles 4'Cold fusion' moves closer to mainstream acceptance 2'Cold fusion' moves closer to mainstream acceptance 3'Cold fusion' moves closer to mainstream acceptance 4
... Ambions MAXIscript In Vitro Transcription Kits ... 1 x 10 9 cpm/g. High ... in ribonuclease protection assays, in situ hybridization, ... be used for the synthesis of modest ...
Mouse H60 Allophycocyanin MAb (Clone 205326) ENTREZ GeneID: 15101...
... 250 ul (125 precipitations). ... easy pellet location.Efficient precipitation ... inert, compatible with most ... protocol. Category: DNA/RNA Synthesis ...
... for monitoring Aldolase tests. 2 levels ... targeted manufacturing values at 4 ± ... IU/L. 30-day shelf life once ... Level 1: 3 x 3 ml; ...
Biology Products: